

# Sergey O Bachurin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8922556/publications.pdf>

Version: 2024-02-01

37  
papers

1,800  
citations

304368

22  
h-index

315357

38  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2191  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. <i>Lancet, The</i> , 2008, 372, 207-215.	6.3	440
2	Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. <i>Medicinal Research Reviews</i> , 2017, 37, 1186-1225.	5.0	248
3	Methylene blue and dimebon inhibit aggregation of TDP43 in cellular models. <i>FEBS Letters</i> , 2009, 583, 2419-2424.	1.3	102
4	Conjugates of $\hat{I}^3$ -Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease. <i>Scientific Reports</i> , 2015, 5, 13164.	1.6	76
5	Esterase profiles of organophosphorus compounds in vitro predict their behavior in vivo. <i>Chemico-Biological Interactions</i> , 2016, 259, 332-342.	1.7	58
6	Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1050-1062.	1.4	57
7	Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. <i>Pharmacological Research</i> , 2018, 129, 216-226.	3.1	56
8	Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment. <i>Scientific Reports</i> , 2017, 7, 45627.	1.6	54
9	Chronic Administration of Dimebon Ameliorates Pathology in TauP301S Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1041-1049.	1.2	48
10	Pharmacological Sequestration of Mitochondrial Calcium Uptake Protects Neurons Against Glutamate Excitotoxicity. <i>Molecular Neurobiology</i> , 2019, 56, 2244-2255.	1.9	48
11	Novel 1,2,4-Thiadiazole Derivatives as Potent Neuroprotectors: Approach to Creation of Bioavailable Drugs. <i>Molecular Pharmaceutics</i> , 2012, 9, 2156-2167.	2.3	47
12	Conjugates of tacrine and 1,2,4-thiadiazole derivatives as new potential multifunctional agents for Alzheimer's disease treatment: Synthesis, quantum-chemical characterization, molecular docking, and biological evaluation. <i>Bioorganic Chemistry</i> , 2020, 94, 103387.	2.0	44
13	Dimebon Slows Progression of Proteinopathy in $\hat{I}^3$ -Synuclein Transgenic Mice. <i>Neurotoxicity Research</i> , 2012, 22, 33-42.	1.3	43
14	Dimebon Attenuates the A $\beta$ -Induced Mitochondrial Permeabilization. <i>Current Alzheimer Research</i> , 2014, 11, 422-429.	0.7	38
15	Overview of novel multifunctional agents based on conjugates of $\hat{I}^3$ -carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease. <i>Chemico-Biological Interactions</i> , 2019, 308, 224-234.	1.7	36
16	Neuroprotective and Cognition-Enhancing Properties of MK801 Flexible Analogs. <i>Annals of the New York Academy of Sciences</i> , 2001, 939, 219-236.	1.8	34
17	Structural Basis for Understanding Structure-Activity Relationships for the Glutamate Binding Site of the NMDA Receptor. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3836-3843.	2.9	33
18	Novel Sites of Neuroprotective Action of Dimebon (Latrepidine). <i>Molecular Neurobiology</i> , 2015, 52, 970-978.	1.9	30

#	ARTICLE	IF	CITATIONS
19	Neurodegenerative disorders – Searching for targets and new ways of diseases treatment. <i>Medicinal Research Reviews</i> , 2021, 41, 2603-2605.	5.0	27
20	New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer’s Disease Treatment. <i>Molecules</i> , 2020, 25, 3915.	1.7	26
21	Conjugates of methylene blue with $\hat{1}^3$ -carboline derivatives as new multifunctional agents for the treatment of neurodegenerative diseases. <i>Scientific Reports</i> , 2019, 9, 4873.	1.6	25
22	Focused design of polypharmacophoric neuroprotective compounds: Conjugates of $\hat{1}^3$ -carbolines with carbazole derivatives and tetrahydrocarbazole. <i>Pure and Applied Chemistry</i> , 2017, 89, 1167-1184.	0.9	24
23	Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2021, 41, 803-827.	5.0	24
24	Pro-neurogenic, Memory-Enhancing and Anti-stress Effects of DF302, a Novel Fluorine Gamma-Carboline Derivative with Multi-target Mechanism of Action. <i>Molecular Neurobiology</i> , 2018, 55, 335-349.	1.9	22
25	Individual Differences in Behavioural Despair Predict Brain GSK-3beta Expression in Mice: The Power of a Modified Swim Test. <i>Neural Plasticity</i> , 2016, 2016, 1-17.	1.0	19
26	Mitochondrial Permeability Transition Pore as a Suitable Target for Neuroprotective Agents Against Alzheimer’s Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 677-685.	0.8	18
27	Concomitant manipulation of murine NMDA- and AMPA-receptors to produce pro-cognitive drug effects in mice. <i>European Neuropsychopharmacology</i> , 2014, 24, 309-320.	0.3	17
28	Novel Positive Allosteric Modulators of AMPA Receptors Based on 3,7-Diazabicyclo[3.3.1]nonane Scaffold. <i>Molecular Neurobiology</i> , 2020, 57, 191-199.	1.9	17
29	Conjugation of Aminoadamantane and $\hat{1}^3$ -Carboline Pharmacophores Gives Rise to Unexpected Properties of Multifunctional Ligands. <i>Molecules</i> , 2021, 26, 5527.	1.7	14
30	Applications of Multi-Target Computer-Aided Methodologies in Molecular Design of CNS Drugs. <i>Current Medicinal Chemistry</i> , 2019, 25, 5293-5314.	1.2	14
31	In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. <i>Medicinal Research Reviews</i> , 2021, 41, 2804-2822.	5.0	13
32	New Therapeutic Property of Dimebon as a Neuroprotective Agent. <i>Current Medicinal Chemistry</i> , 2019, 25, 5315-5326.	1.2	12
33	Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors: N-Functionalization Determines the Multitarget Anti-Alzheimer’s Activity Profile. <i>Molecules</i> , 2022, 27, 1060.	1.7	10
34	Novel conjugates of 4-amino-2,3-polymethylenequinolines and vanillin as potential multitarget agents for AD treatment. <i>Mendeleev Communications</i> , 2021, 31, 606-608.	0.6	8
35	Physicochemical property profile for brain permeability: comparative study by different approaches. <i>Journal of Drug Targeting</i> , 2016, 24, 655-662.	2.1	7
36	Bis- $\hat{1}^3$ -carbolines as new potential multitarget agents for Alzheimer’s disease. <i>Pure and Applied Chemistry</i> , 2020, 92, 1057-1080.	0.9	6

#	ARTICLE	IF	CITATIONS
37	A bioisostere of Dimebon/Latrepidine delays the onset and slows the progression of pathology in FUS transgenic mice. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 765-775.	1.9	4